K. Abdallah's research while affiliated with Merck & Co. and other places

Publication (1)

Full-text available
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs...


... 4 Without early identification and proper management, irAEs can develop into severe complications, resulting in treatment discontinuation or failure and even death, which poses a considerable challenge in daily clinical care. 5,6 Isolated RCTs and their meta-analyses present the highest quality of evidence and are the basis for guidelines issued by healthcare organisations. 7 However, the evaluation of entire profiles of rare irAEs derived from RCTs data is difficult owing to their stringent diagnostic standards and selection criteria, relatively small sample sizes, and limited follow-up duration. ...